A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells.

Yasutaka Fujita, Masuhiro Nishimura, Natsuki Watanabe Komori, Tamaki Wada, Chikage Shirakawa, Taichi Takenawa, Osamu Sawamoto, Masako Doi
Author Information
  1. Yasutaka Fujita: Research and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, Japan.
  2. Masuhiro Nishimura: Research and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, Japan.
  3. Natsuki Watanabe Komori: Research and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, Japan.
  4. Tamaki Wada: Research and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, Japan.
  5. Chikage Shirakawa: Research and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, Japan.
  6. Taichi Takenawa: Research and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, Japan.
  7. Osamu Sawamoto: Research and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, Japan.
  8. Masako Doi: Research and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, Japan.

Abstract

INTRODUCTION: Stem cells for therapy are often suspended in a preservation solution, such as normal saline or lactated Ringer's solution, for a short time before intravenous infusion. However, these solutions are not necessarily ideal for maintaining cell viability and preventing the sedimentation of cells during storage and infusion. In this study, we attempted to optimize the compositions of preservation solutions, which could affect the efficacy and safety of stem cell therapy.
METHODS: We determined the characteristics of a preservation solution that would optimize cell viability and the percentage of cells in the supernatant using human adipose-derived mesenchymal stromal cells (hADSCs). We compared solutions that differed by electrolytes (e.g., normal saline and Ringer's solution) and the concentrations of dextran 40 and trehalose. The effects of the solutions on hADSCs were evaluated by assessing cell surface markers, colony-forming capacity, differentiation potential, and cell concentrations in the infusion line.
RESULTS: Optimized preservation solutions consisted of lactated Ringer's solution with 3% trehalose without or with 5% dextran 40 (LR-3T and LR-3T-5D, respectively). The cell viabilities after 24 h of storage at 5 °C in LR-3T and LR-3T-5D were 94.9% ± 2.4% and 97.6% ± 2.4%, respectively. The percentage of cells in the supernatant after 1 h of storage at room temperature in LR-3T-5D was 83.5% ± 7.6%. These solutions preserved the percentage of cell surface marker-positive cells, the colony-forming capacity, and the adipogenic and osteogenic differentiation ability in hADSCs for at least 24 h after preservation at 5 °C and 25 °C.
DISCUSSION: We determined the optimal composition of preservation solutions for hADSCs and confirmed the effects of these solutions on cell viability and the stability of cell characteristics . Our results suggest that LR-3T and LR-3T-5D can help maintain the quality of stem cells for therapy during preservation and infusion. However, further research is needed on the efficacy and safety of the solutions in different therapeutic cell lines before clinical use.

Keywords

References

  1. J Cardiothorac Vasc Anesth. 2019 Jan;33(1):209-222 [PMID: 30029992]
  2. Minerva Anestesiol. 2005 Dec;71(12):741-58 [PMID: 16288182]
  3. World J Gastroenterol. 2015 Nov 21;21(43):12334-50 [PMID: 26604641]
  4. Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H455-65 [PMID: 26683902]
  5. Methods Enzymol. 2007;428:209-25 [PMID: 17875419]
  6. J Hepatol. 2015 Apr;62(1 Suppl):S157-69 [PMID: 25920085]
  7. Stem Cells Dev. 2015 Sep 15;24(18):2091-100 [PMID: 26068030]
  8. Cytotherapy. 2006;8(4):315-7 [PMID: 16923606]
  9. Stem Cells Cloning. 2015 Aug 28;8:117-24 [PMID: 26357483]
  10. Adv Physiol Educ. 2004 Dec;28(1-4):135-8 [PMID: 15545341]
  11. Adv Physiol Educ. 2004 Dec;28(1-4):155-9 [PMID: 15545344]
  12. Protein Sci. 2009 Jan;18(1):24-36 [PMID: 19177348]
  13. Transplantation. 1999 Jul 15;68(1):110-7 [PMID: 10428277]
  14. J Am Chem Soc. 2007 Aug 29;129(34):10567-74 [PMID: 17676844]
  15. Contrib Nephrol. 2006;152:142-160 [PMID: 17065810]
  16. Surgery. 1994 Jan;115(1):102-7 [PMID: 8284750]
  17. Biomed Res Int. 2017;2017:8910821 [PMID: 28210629]
  18. Yonsei Med J. 2004 Dec 31;45(6):1107-14 [PMID: 15627304]
  19. Adv Physiol Educ. 2004 Dec;28(1-4):143-54 [PMID: 15545343]
  20. Cryobiology. 2007 Feb;54(1):77-86 [PMID: 17289012]
  21. Cell Transplant. 2010;19(3):291-7 [PMID: 19995483]
  22. PeerJ. 2017 May 17;5:e3301 [PMID: 28533959]
  23. PLoS One. 2015 Aug 31;10(8):e0136991 [PMID: 26323092]
  24. Cell Stem Cell. 2015 Jul 2;17(1):11-22 [PMID: 26140604]
  25. Inflamm Res. 2014 Nov;63(11):907-17 [PMID: 25098205]
  26. Stem Cells Transl Med. 2015 Mar;4(3):207-10 [PMID: 25637191]

Word Cloud

Created with Highcharts 10.0.0cellscellsolutionspreservationsolutionRinger'smesenchymalstromalhADSCsLR-3T-5Dtherapylactatedinfusion40trehaloseLR-3Tviabilitystoragepercentagehumanadipose-deriveddextran3%normalsalineHoweveroptimizeefficacysafetystemdeterminedcharacteristicssupernatantconcentrationseffectssurfacecolony-formingcapacitydifferentiation5%respectively24 h5 °C4%INTRODUCTION:StemoftensuspendedshorttimeintravenousnecessarilyidealmaintainingpreventingsedimentationstudyattemptedcompositionsaffectMETHODS:usingcompareddifferedelectrolytesegevaluatedassessingmarkerspotentiallineRESULTS:Optimizedconsistedwithoutviabilities949% ± 2976% ± 21 hroomtemperature835% ± 76%preservedmarker-positiveadipogenicosteogenicabilityleast25 °CDISCUSSION:optimalcompositionconfirmedstabilityresultssuggestcanhelpmaintainqualityresearchneededdifferenttherapeuticlinesclinicalusepairadiposetissue-derivedCellDextranHumanMSCsTrehalose

Similar Articles

Cited By (5)